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ABSTRACT 
Objective: The objective of the study was to enhance solubility of Lurasidone HCl, an atypical antipsychotic drug, by formulating self-micro 
emulsifying drug delivery system (SMEDDS) and its characterization. 
Methods: Solubility study of Lurasidone hydrochloride (LH) was carried out in various surfactants, co surfactants and oils. Pseudo ternary phase 
diagrams were constructed to identify the self-micro emulsification region. Screening was done so as to determine the proper combination of 
components. Based on this, LH SMEDDS were prepared using Cremophor RH40 (surfactant), Soluphor P (co-surfactant) and Capmul MCM (oil). The 
preconcentrate SMEDDS were evaluated for clarity(visual), precipitation, % transmittance, robustness to dilution, freeze thawing, particle size 
distribution and zeta potential and adsorbed SMEDDS were evaluated for drug content, flow properties, in-vitro dissolution and ex-vivo diffusion 
studies.  
Results: The optimized LH SMEDDS composed of 14% Cremophor RH40, 68% Soluphor P, 18% Capmul MCM with a particle size of 3.95 µm and 
zeta potential of more than 50 mV showing 80% dissolution in 60 min. 
Conclusion: The results of this study prove that SMEDDS help in improving the solubility, dissolution and bioavailability of lurasidone 
hydrochloride.  
Keywords: Lurasidone Hydrochloride, Solubility enhancement, SMEDDS, In-vitro dissolution, Ex-vivo diffusion. 
 
INTRODUCTION 
Lurasidone Hydrochloride (Brand name: Latuda) was approved in 
2010 by USFDA as the tenth atypical antipsychotic for the treatment of 
schizophrenia. It belongs to a class of drugs known as benzoisothiazol 
or azapirone derivatives, and is most similar to ziprasidone (Geodon) 
among the available atypical antipsychotics. It is a second generation 
antipsychotic, which may be better tolerated than the older 
antipsychotics. Atypical antipsychotics quickly replaced the older 
antipsychotics, such as chlorpromazine and haloperidol, as first-line 
treatment for schizophrenia and other psychotic disorders, because of 
their lower risks of extra pyramidal symptoms as well as better 
effectiveness in treating negative symptoms in schizophrenia [1]. 
LH has a poor bioavailability (<12% in all species tested) [2]. This is 
because of its poor solubility. It is found to be soluble in methanol 
and insoluble in acetone, ethanol and water. Till date solubility 
enhancement of LH has been tried by forming solid dispersions [3]. 
As compared to other enhancement techniques, SMEDDS help in 
increasing the absorption of lipophilic drugs taken orally. They 
spread readily in the GI tract, and the digestive motility of the 
stomach and the intestine provides the agitation necessary for self-
emulsification. Also they can be encapsulated in hard or soft gelatin 
capsules or can be converted to solid state (Solid SEDDS/SMEDDS). 
Moreover they help in improving the efficacy of the drug allowing 
dose reduction and side effect minimization [4]. The potential of 
microemulsions or self-microemulsifying drug delivery systems 
(SMEDDS) in the improvement of the bioavailability and therapeutic 
performance of the hydrophobic agents has been very well-
established for drugs like tacrolimus, glibenclamide, fenofibrate & 
furosemide [5-9]. The rationale of this project was to develop 
SMEDDS of Lurasidone HCl which will help in enhancing its 
solubility and thereby increase its bioavailability. Hence the present 
study was aimed to develop and evaluate an optimal SMEDDS 
formulation containing LH. 
MATERIALS AND METHODS 
LH was obtained as a gift sample from Glenmark Generics Limited 
(Gujarat, India). Capmul MCM, Captex 355 and Captex 200P were 
obtained as gift samples from Abitec (USA). Maisine, Peceol, 
Labrasol and Transcutol HP were obtained as gift samples from 
Gattefosse India Pvt. Ltd. (Mumbai, India). Kolliphor 
RH40(Cremophor RH40), Kolliphor EL(Cremophor EL) and Kollisolv 
P(Soluphor P) were obtained as gift samples from BASF South East 
Asia Pvt Ltd (India).  
Span 20, Span 80, Tween 20, Tween 80 and Propylene Glycol (all AR 
grade) were obtained from SDFCL (Mumbai, India). Microcrystalline 
cellulose (MCC) was obtained from Research Lab-Fine Chemical 
Industries Pvt Ltd (Mumbai, India). Aeroperl 300 Pharma was 
purchased from Evonik (India). All other chemicals and reagents 
used were of AR grade. 
Characterization of liquid SMEDDS 
Solubility studies  
The saturation solubility of LH was evaluated in various oils, 
surfactants, and cosurfactants as given in  fig. 1. In this study, an excess 
amount of LHwas added to 2 ml of each of the vehicle in eppendorf 
tubes and the mixture was mixed on a cyclomixer till it remained 
undissolved.  
Then they were put in an orbital shaker for 24 h under ambient 
temperature to attain equilibrium. Aliquots of supernatant were 
diluted with methanol and analyzed for dissolved drug by the UV 
spectrophotometry (Lambda 25 UV/Visible spectrometer with UV Win 
lab software, Perkin Elmer, MA, USA) at λmax 315 nm.  
Water uptake studies 
Using different combinations of surfactant: cosurfactant: oil, the 
amount of water uptake in each mixture was determined. The 
mixtures showing maximum water uptake were chosen and carried 
forward for drug loading. 
Drug loading 
Since LH has a poor solubility hence the mixtures showing maximum 
water uptake were loaded with 20 mg (dose) drug. From these batches, 
the mixture containing Cremophor RH40, Soluphor P and Capmul MCM 
was found to solubilize 20 mg drug. Hence this was selected and ternary 
phase diagrams were constructed for further optimization. 
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Pseudo ternary phase diagrams  
Pseudo ternary phase diagrams of oil, surfactant/cosurfactant 
(S/CoS), and water were developed using the water titration 
method. The mixtures of oil and S/CoS at certain weight ratios were 
diluted with water in a drop wise manner. For each phase diagram 
(fig. 2) at a specific ratio of S/CoS (i.e.1:1, 1:2wt./wt.), a transparent 
and homogenous mixture of oil and S/CoS was formed by vortexing 
for 5 min. Then each mixture was titrated with water and visually 
observed for phase clarity and flowability. The concentration of 
water at which turbidity-to-transparency and transparency 
to-turbidity transitions occurred was derived from the weight 
measurements. These values were then used to determine the 
boundaries of the microemulsion domain corresponding to the 
chosen value of oils, as well as the S/CoS mixing ratio. To determine 
the effect of drug addition on the microemulsion boundary, drug 
loading was carried out in the ratio which showed best 
microemulsion formation. Phase diagrams were then constructed 
using TriDraw Version 4.5 software. 
Preparation of liquid SMEDDS  
A series of SMEDDS formulations were prepared using Cremophor 
RH40, Soluphor P as the S/CoS combination and Capmul MCM as the oil. 
Different ratios of Cremophor RH40 and Soluphor P (1:1, 1:2, 1:3, 1:4 
and 4:1) with Capmul MCM in ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 
and 9:1 w/w were tried and maximum water incorporated was weighed. 
In all the formulations, drug (20 mg) was loaded. Briefly, accurately 
weighed LH was placed in a test tube, and oil, surfactant, and 
cosurfactant were added. Then the components were mixed by gentle 
stirring and vortex mixing and were heated on a magnetic stirrer, until 
LH was perfectly dissolved. The microemulsion thus formed was then 
stored at room temperature and evaluated [6, 7]. 
Evaluation of liquid SMEDDS 
Drug excipient compatibility study 
IR spectroscopy was conducted for drug and formulation using a 
FTIR spectrophotometer (Perkin Elmer, RXI, USA) and spectrum was 
recorded in the region of 4000 to 400 cm-1.  
Clarity test  
0.5 ml of pre-concentrate SMEDDS was diluted with 250 ml distilled 
water. It was tested against white and black background and 
turbidity was checked for any visible particles [6]. 
Precipitation by visual inspection 
0.5 ml of pre-concentrate SMEDDS was diluted with 100 ml of distilled 
water in a glass beaker at room temperature and the content was 
gently stirred. The tendency to form a transparent or clear emulsion 
was judged as good and bad when the formation was poor or milky in 
appearance. The prepared microemulsions were studied for this and 
observed for 24 h any sign of drug precipitation [7] 
% Transmittance measurements 
The percentage transmittance of preconcentrate at 650 nm was 
determined using UV spectrophotometer keeping distilled water as 
a blank. Each measurement was carried out in triplicate. 
Thermodynamic stability studies [8-10] 
Microemulsions are thermodynamically stable formulation and are 
formed at a particular concentration of oil, surfactant and water, 
with no phase separation, creaming and cracking. The selected 
formulations were subjected to different thermodynamic stability by 
using freeze thaw cycle and centrifugation stress tests. 
Centrifugation test 
In this, the samples were centrifuged at 10,000 rpm for 10 min and then 
were examined for whether the system is monophasic or biphasic. 
Freeze thawing 
Freeze thawing was employed to evaluation the stability of the 
formulation. The microemulsion formulation was subjected to freeze 
thaw cycle, which included freezing at 4ºC for 24 h followed by 
thawing at 40 ºC for 24 h The various formulations were then 
subjected to centrifugation at 3000 rpm for 5 min. The formulations 
were then visually observed for phase separation. 
Dispersibility studies 
Pre concentrate SMEDDS were diluted to 100 times with various 
dissolution media viz. water, buffer pH 1.2 and buffer pH 6.8. The 
diluted micro-emulsions were stored for 24 h and observed for any 
sign of phase separation or drug precipitation thereby indicating its 
dispersibility. 
Particle size distribution (PSD) and zeta potential 
The optimized batch was outsourced for determination of particle 
size and zeta potential. A dispersion of preconcentrate SMEDDS was 
prepared. After ensuring complete dispersion of the formulation the 
droplet size of resultant micro-emulsion was determined by photon 
correlation spectroscopy that analyze the fluctuation in light 
scattering due to the Brownian motion of the droplets as function of 
time using a Zetasizer Nano S 90 (Malvern Instruments, U. K). 
Preparation of solid SMEDDS 
Preconcentrate SMEDDS were adsorbed on solid carrier like MCC 
and Aeroperl® 300 Pharma (silicon dioxide). Flow properties and 
drug content were determined and based on the amount of solid 
carrier used; the final solid carrier was selected. 
Evaluation of solid SMEDDS 
Flow properties 




Drug content  
0.1 g of MCC adsorbed SMEDDS were taken and diluted with 
methanol. The concentration of drug in this was determined using 
UV spectrophotometer at 315 nm. Similar process was carried out 
for determining drug content in Aeroperl adsorbed SMEDDS. 
In-vitro dissolution rate studies  
For in vitro dissolution study, adsorbed SMEDDS equivalent to 20 
mg of LH filled in hard gelatin capsules was carried out using USP 
dissolution Apparatus-type I (Basket) &II (Paddle) to check release 
pattern. The dissolution was maintained at 37 ºC±0.5 ºCand the 
paddle and basket speed was set at 50 rpm both. 5 ml aliquots were 
withdrawn at of 5, 10, 15, 20, 25, 30, 45, 60 min intervals. At the 
same time 5 ml of fresh media was replaced in the vessel. The 
samples were analyzed for drug content by spectrophotometric 
method at λmax 315 nm using UV visible double beam 
spectrophotometer [11]. 
Ex-vivo studies 
All experiments and protocols described in this animal study were 
approved by the Institutional Animal Ethics Committee (Approval 
no: CPCSEA/IAEC/SPTM/P-17/2015) and were in accordance with 
the guidelines of the Committee for Purpose of Control and 
Supervision of Experiments on Animals and Government of India. To 
check the intestinal permeability, small portion of small intestine of 
Albino wistar rats was isolated and used for the ex vivo permeability 
study. The tissue was thoroughly washed with pH 3.8 McIlvaine’s 
buffer to remove any mucous and lumen contents and tied with a 
thread at one end. The preconcentrate SMEDDS, 0.5 g (equivalent to 
20 mg LH) was filled in the sac. Around 30 ml of McIlvaine’s buffer 
pH 3.8 was used. The other end was again tied with a knot thereby 
forming a sac containing the microemulsion. Aliquots were taken 
from the medium at 5,10,15,20,25,30,45 and 60 min and suitably 
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diluted further. The absorbance was measured using a UV-Visible 
spectrophotometer at a wavelength of 315 nm.  
The amount of drug diffused (%) was calculated against time and 
plotted on a graph as shown in fig. 6 [12]. 
RESULTS AND DISCUSSION 
Solubility studies 
The components used and their concentration have profound effects 
on the various characteristics of microemulsion, such as particle 
size, emulsification time and in vitro drug release. Hence, it is 
important to optimize the quantities of the SMEDDS components 
after initial selection. The initial selection of the components can be 
on the on the basis of their ability to solubilize the drug. [13] 
LH is a poorly water soluble drug and the permeability efficiency of 
the drug is also not known. Hence initially, a saturation solubility 
study was performed in a preselected set of surfactants, co-
surfactants and oils.  
The results as given showed that LH showed good solubility in Peceol, 
Capmul MCM, Kollisolv P (Soluphor P), Cremophor RH40 and 
Propylene Glycol as seen in fig. 1. Batches prepared using Peceol as oil 
showed separation of the mixture into two layers. Hence Peceol was 
not taken for water uptake studies. Hence three batches containing 
Cremophor RH40: Transcutol HP: Capmul MCM; Cremophor RH40:  
Propylene glycol: Capmul MCM and Cremophor RH 40: Soluphor P: 
Capmul MCM as surfactant, co-surfactant and oil were prepared and 
evaluated for their water uptake. 
 
 
Fig. 1: Solubility of LH in different excipients 
 
Water uptake studies 
Of the various mixtures, four of them showed maximum water uptake. 
Hence these four batches were then tested for drug loading of 20 mg. 
Drug loading 
The mixture containing Cremophor RH40, Soluphor P and Capmul 
MCM could be incorporated with 20 mg of drug easily. Hence 
ternary diagrams were constructed using this mixture with the help 
of TriDraw software (Version 4.1a). From these diagrams (fig. 2) a 
microemulsion region was obtained. The shaded region indicates the 
microemulsion area. A wider microemulsion region indicates better 
microemulsifying ability [14]. A series of points from the 
microemulsion region was selected and drug loading was checked 
again at these points. 
Following are the ternary phase diagrams for different ratios of 
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Fig. 2: Ternary phase diagrams for the ratios 
 
From each of the diagram different concentrations were taken from 
oil, cosurfactant and surfactant and drug loading was tried. It was 
found that Batch L3, L4, L5 and L6 showed a clear microemulsion 
even on adding 20 mg of drug.  
Hence these batches were subjected to evaluation 
Drug excipient compatibility study 
An FTIR spectrum is used to determine the interaction between the 
drug and the excipients used in the formulation. Lurasidone HCl 
shows peaks at 738±4, 776±4, 963±4, 1143±4, 1181±4, 1288±4, 
1314±4, 1367±4, 381±4, 1423±4, 1493±4, 1687±4, 1761±4, 2848±4, 
2879±4, 2929±4, and 3417±4 cm-1. The formulation spectrum 
showed these drug peaks as well as additional peaks of the 
surfactant and cosurfactant used. However, the drug peaks were not 
affected by the presence of excipients, thus proving that the drug 
was compatible with the excipients used. 
The results for test for clarity, precipitation, %transmittance and 
stability cycles (centrifugation, freeze thawing and dispersibility 
study) were found to be as given in table 1. 
Particle size and zeta potential 
The droplet size/particle size is a crucial factor in self-emulsification 
performance because it determines the rate and extent of drug 
release, as well as absorption. The significance of emulsion droplet 
size in the in vivo performance of the formulation is not yet clear. 
Tarr and Yalkowsky have demonstrated enhancement of the rate of 
intestinal absorption of cyclosporine through the reduction of the 
emulsion droplet size [14]. 
One of the reasons for enhanced absorption observed with the small 
particle size is the larger surface area available for partitioning of 
the drug and for lipase activity. However, as per a recent statement 
by Pouton [15], the role of droplet size is less important than it was 
assumed by some authors due to the fact that digestion will take 
place directly after the lipid dispersion leaves the stomach and at 
this stage particle size will have no or little effect. The results for 
particle size and zeta potential obtained were as given in fig. 3. 
These results showed particle size of 3.957 µm and zeta potential of 
above 50 mV which proved that the microemulsion formed was 
stable. The average diameter of microemulsion droplets is mainly 
due to cosurfactant molecules penetrating the surfactant film, 
lowering the fluidity and surface viscosity of the interfacial film, 
decreasing the radius of curvature of the microdroplets and forming 
a transparent system [13]. 
Preparation and evaluation of adsorbed SMEDDS 
The pre concentrate microemulsion was adsorbed using suitable 
solid carriers-MCC (Microcrystalline cellulose) and Aeroperl (silicon 
dioxide) so as to form adsorbed SMEDDS to be filled in the capsule. 
On the basis of drug content and flow properties obtained the 
optimum solid carrier was selected as given in table 2 
 
Table 1: Results for evaluation tests performed 
Tests performed  Batch L3 Batch L4 Batch L5 Batch L6 
 Clarity √ √ √ √ 
Precipitation √ X X X 
% Transmittance 75.09 76.4 81.2 85 
Freeze thawing X X X X 
Dispersibility studies X X X X 
Where, √-Passed and x-Failed, On the basis of evaluation tests Batch L6 was selected which consisted of a ratio of 1:4 of surfactant: co-surfactant. 
The complete mixture contained 14% Cremophor RH40, 68% Soluphor P, 18% Capmul MCM in thepreconcentrate SMEDDS formulation Batch(L6) 
was then taken forward for particle size analysis and zeta potential measurement since it satisfied all the evaluation tests.  
 
Table 2: Evaluation of adsorbed SMEDDS on different solid carrier (n=3) 




% Drug content 
(mean±SD) 
MCC 42.23±0.07 1.819±0.22 89.219±0.43  
Aeroperl 300 Pharma(silicon dioxide) 17.6±0.21 1.22±0.12 93.753±2.60 
Carr’s index was found to be 17.6 % and Hausner’s ratio was 1.22 for Aeroperl adsorbed SMEDDS which was within the acceptable limits. Hence 
Aeroperl was selected as a suitable adsorbant. 
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Fig. 3: Report of particle size distribution 
 
 
Fig. 4: Report of zeta potential 
 
In-vitro dissolution rate studies 
Next evaluation parameter was determining the release of drug from 
capsules in-vitro. Dissolution was carried out using USP Apparatus I & II.  
 
 
Fig. 5: Release pattern of adsorbed SMEDDS using USP 
Apparatus I and II (n=3) 
 
Apparatus II showed 85 % release of the drug at the end of 60 min in 
comparison to 72 % release shown by Apparatus I as seen in fig. 
Hence apparatus II was selected as the preferred USP Apparatus to 
be used to carry out in-vitro dissolution of capsules.  
Comparison of pure drug with formulation 
A comparison of the drug release was done between pure drug in 
capsule and finished formulation in capsule. Fig. 6 shows that there 
was about 15 % release of pure drug from capsule at the end of 1 h 
but a 5–6 folds increase was obtained at 5 min interval by capsule 
containing SMEDDS showing enhancement in solubility due to 
reduction in particle size by micro emulsification 
 
 
Fig. 6: A comparison of the % release of drug from capsule 
containing pure drug and SMEDDS respectively (n=3) 
 
Diffusion profile 
To understand the characteristics of drug permeation, ex vivo 
intestinal tissue permeation study was carried out across the small 
intestine of male Albino Wistar rats. The amount of LH permeated 
across rat intestinal tissue was determined by UV 
Spectrophotometer. The profile of drug permeation is shown in fig. 
7. In the first half hour, the permeation of drug through the intestinal 
membrane from the preconcentrate SMEDDS was 64.109±0.707. 
More than 50 % of the drug permeated across the intestine tissue 
within half an hour from. 
 




A SMEDDS formulation of poorly water soluble drug, LH was 
formulated by directly filling into hard gelatin capsules used for oral 
administration. The SMEDDS of lurasidone HCl were optimized by 
using parameters like clarity, precipitation, % transmittance, 
robustness to dilution, freeze thawing, particle size determination, 
zeta potential, drug content, flow properties and in vitro drug 
release. The optimized LH SMEDDS is composed of 14% 
CremophorRH40, 68% Soluphor P, 18% Capmul MCM and complete 
drug release which showed limited dissolution rate. The results of 
the study show the ability of SMEDDS to enhance solubility and 
dissolution of poorly water soluble compounds like lurasidone 
hydrochloride. 
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